Edwards Lifesciences Corporation (EW) Shares Sold by Moors & Cabot Inc.

Moors & Cabot Inc. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.4% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 22,902 shares of the medical research company’s stock after selling 569 shares during the quarter. Moors & Cabot Inc.’s holdings in Edwards Lifesciences Corporation were worth $2,703,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of EW. UBS Asset Management Americas Inc. grew its holdings in Edwards Lifesciences Corporation by 7.8% during the 1st quarter. UBS Asset Management Americas Inc. now owns 574,126 shares of the medical research company’s stock worth $54,008,000 after acquiring an additional 41,636 shares during the last quarter. Raymond James Financial Services Advisors Inc. grew its holdings in Edwards Lifesciences Corporation by 9.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 7,821 shares of the medical research company’s stock worth $736,000 after acquiring an additional 665 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Edwards Lifesciences Corporation during the 1st quarter worth about $291,000. Artisan Partners Limited Partnership bought a new stake in Edwards Lifesciences Corporation during the 1st quarter worth about $63,097,000. Finally, Comerica Securities Inc. bought a new stake in Edwards Lifesciences Corporation during the 1st quarter worth about $319,000. 82.08% of the stock is currently owned by hedge funds and other institutional investors.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,300 shares of the business’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $114.68, for a total value of $607,804.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Michael A. Mussallem sold 32,900 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $114.80, for a total value of $3,776,920.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 182,201 shares of company stock worth $20,768,154. Insiders own 2.13% of the company’s stock.

A number of equities research analysts have commented on the stock. Barclays PLC reissued an “equal weight” rating and set a $120.00 price objective on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Canaccord Genuity reissued a “buy” rating and set a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. BidaskClub downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Jefferies Group LLC restated a “buy” rating and set a $115.00 target price on shares of Edwards Lifesciences Corporation in a research report on Friday, June 30th. Finally, Zacks Investment Research downgraded shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Seven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $120.75.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded down 0.15% during mid-day trading on Friday, hitting $111.46. 1,423,309 shares of the company were exchanged. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The firm has a 50 day moving average of $111.90 and a 200 day moving average of $110.77. The company has a market capitalization of $23.54 billion, a price-to-earnings ratio of 33.81 and a beta of 0.62.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842.00 million for the quarter, compared to analyst estimates of $839.16 million. During the same period in the previous year, the firm earned $0.76 earnings per share. The company’s revenue was up 10.9% compared to the same quarter last year. Equities research analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences Corporation (EW) Shares Sold by Moors & Cabot Inc.” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/10/07/edwards-lifesciences-corporation-ew-shares-sold-by-moors-cabot-inc.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply